NCT04311463View on ClinicalTrials.gov

Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

January 2, 2021

Study Completion Date

January 2, 2021

Conditions

Anxiety Disorders

Interventions

DRUG

Paroxetine hydrochloride

Paroxetine hydrochloride will be administered.

DRUG

PAXIL (Paroxetine hydrochloride )

PAXIL will be administered.

Trial Locations (1)

66260

GSK Investigational Site, Monterrey

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT04311463 - Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants | Biotech Hunter | Biotech Hunter